Abstract
Background Depression is prevalent among patients with congestive heart failure (CHF) and is associated with increased mortality and healthcare utilization. However, most research has focused on high-income countries, leaving a gap in knowledge regarding the relationship between depression and CHF in low-to-middle-income countries (LMICs). This study aimed to delineate depressive symptom trajectories and identify potential risk factors for poor outcomes among CHF patients.
Methods Longitudinal data from 783 patients with CHF from public hospitals in Karachi, Pakistan was analyzed. Depressive symptom severity was assessed using the Beck Depression Inventory (BDI). Baseline and 6-month follow-up BDI scores were clustered through Gaussian Mixture Modeling to identify distinct depressive symptom subgroups and extract trajectory labels. Further, a random forest algorithm was utilized to determine baseline demographic, clinical, and behavioral predictors for each trajectory.
Results Four depressive symptom trajectories were identified: ‘good prognosis,’ ‘remitting course,’ ‘clinical worsening,’ and ‘persistent course.’ Risk factors associated with persistent depressive symptoms included lower quality of life and the New York Heart Association (NYHA) class 3 classification of CHF. Protective factors linked to a good prognosis included less disability and a non-NYHA class 3 classification of CHF.
Conclusions By identifying key characteristics of patients at heightened risk of depression, clinicians can be aware of risk factors and better identify patients who may need greater monitoring and appropriate follow-up care.
To the best of our knowledge, this is the first study to use machine learning techniques to investigate depressive symptom trajectories in CHF patients from an LMIC.
Four distinct depressive symptom trajectories were identified, ranging from good prognosis to persistent depressive symptoms.
This study highlights protective and risk factors associated with these trajectories based on patients’ demographics and clinical presentations at baseline.
Personalized interventions based on identified protective factors for high-risk CHF patients could enhance both mental health and cardiovascular outcomes.
Early detection and management of depression, particularly in patients with poor quality of life or advanced heart failure, may help reduce healthcare utilization and mortality.
This study emphasizes the importance of routine depression screening in CHF patients, especially in LMICs, to enhance overall patient care and outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The data used in this study was funded by the Pakistan Institute of Living and Learning (PILL) (Grant ID: 004/10), Karachi, Pakistan.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at the Dow University of Health Sciences, Karachi approved the protocol of the current study. All study procedures were conducted in accordance with the ethical standards outlined in the Declaration of Helsinki of 1975, as revised in 1983. Written informed consent was obtained from participants who met the inclusion criteria.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data referred to in this manuscript is not publicly available due to privacy restrictions. However, the code used for analysis is provided to ensure reproducibility and transparency.
